Activity of anti-CR3-RP polyclonal antibody against biofilms formed by Candida auris, a multidrug-resistant emerging fungal pathogen

  • Jaroslava Dekkerová
  • Jose L. Lopez-Ribot
  • Helena BujdákováEmail author
Original Article


Fungal biofilm has remained a serious medical problem that complicates treatment of mycoses. In particular, once biofilms are formed, they display high levels of resistance against most common antifungals. Candida auris is currently considered as a serious emerging fungal pathogen frequently exhibiting high levels of resistance to antifungals. Recent studies have confirmed that C. auris shares similarity with Candida albicans in regards to virulence-associated proteins involved in adherence and biofilm development. Complement receptor 3-related protein (CR3-RP) is one of the key surface antigens expressed by Candida species during biofilm formation. Here, we have investigated the presence of this cell surface moiety on the surface of C. auris, as well as the potential of anti-CR3-RP polyclonal antibody (Ab) to inhibit biofilm formation by this emerging fungal pathogen. Using indirect immunofluorescence and ELISA, we were able to confirm the presence of CR3-RP in C. auris cells within biofilms. Further, not only anti-CR3-RP Ab was able to inhibit biofilm formation by multiple C. auris strains when added during the adherence phase, but it also demonstrated activity against C. auris 24-h pre-formed biofilms, which compared favorably to levels of inhibition achieved by treatment with current conventional antifungals fluconazole, amphotericin B, and caspofungin. Overall, our data demonstrate the presence of this antigen on the surface of C. auris and points to the potential of anti-CR3-RP Ab in eradication of biofilms formed by this novel fungal pathogen.


CR3-RP Polyclonal antibody Biofilm Resistance Candida auris 



The authors wish to thank Daniel Montelongo-Jauregui, MSc. (The University of Texas at San Antonio, TX, USA) for help with performing fluorescence microscopy of indirect immunofluorescence.


This work was supported by the Slovak Research and Development Agency under contract no. [APVV-15-0347 to H. B.], and by the grant VEGA [1/0628/15 to H. B.] supported by the Ministry of Education, Science, Research and Sport of the Slovak Republic. This research was also supported by Fulbright Commission in Slovak Republic (J. D. was the Fulbright Visiting Student Researcher at J.L.L.R lab during period Sept 2017–Feb 2018). J.L.L.R acknowledges support by the Margaret Batts Tobin Foundation.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Not applicable.

Informed consent

Not applicable.

Supplementary material

10096_2018_3400_MOESM1_ESM.docx (202 kb)
ESM 1 (DOCX 202 kb)


  1. 1.
    Heidenreich F, Dierich MP (1985) Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b. Infect Immun 50:598–600Google Scholar
  2. 2.
    Bujdáková H, Würzner R, Klobušický M, Dierich MP (1997) Expression and quantification of the iC3b-binding protein in different Candida albicans strains and their morphological stages. FEMS Immunol Medical Microbiol 18:147–152CrossRefGoogle Scholar
  3. 3.
    Paulovičová E, Bystrický S, Machová E, Bujdáková H (2008) Immune responsiveness of a novel peptidoglycan conjugate prepared from surface Candida immunogens: mannan and CR3-related protein. FEMS Immunol Med Microbiol 53:421–428CrossRefGoogle Scholar
  4. 4.
    Calderone RA (1995) Recognition of endothelial cells by Candida albicans: role of complement-binding proteins. Can J Bot 73:1154–1159CrossRefGoogle Scholar
  5. 5.
    Hostetter MK (2008) The iC3b receptor of Candida albicans and its role in pathogenesis. Vaccine 26:108–1012CrossRefGoogle Scholar
  6. 6.
    Bujdáková H, Paulovičová E, Borecká-Melkusová S et al (2008) Antibody response to the 45kDa Candida albicans antigen in an animal model and potential role of the antigen in adherence. J Med Microbiol 57:1466–1472CrossRefGoogle Scholar
  7. 7.
    Bujdáková H, Paulovičová E, Paulovičová L, Šimová Z (2010) Participation of the Candida albicans surface antigen in adhesion, the first phase of biofilm development. FEMS Immunol Med Microbiol 59:485–492CrossRefGoogle Scholar
  8. 8.
    Chupáčová J, Borhi E, Morace G et al (2018) Anti-biofilm activity of antibody directed against surface antigen CR3-RP - comparison of Candida albicans and Candida dubliniensis. FEMS Pathog Dis 76(1).
  9. 9.
    Satoh K, Makimura K, Hasumi Y et al (2009) Candida auris sp. nov., a novel novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 53:41–44CrossRefGoogle Scholar
  10. 10.
    Chowdhary A, Sharma C, Meis JF (2017) Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 13(5):e1006290 CrossRefGoogle Scholar
  11. 11.
    Dolande M, Garcia N, Capote AM et al (2017) Candida auris: antifungal multi-resistant emerging yeast. Curr Fungal Infect Rep 11:197–202CrossRefGoogle Scholar
  12. 12.
    Larkin E, Hager C, Chandra J et al (2017) The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother 61:e02396–e02316. CrossRefGoogle Scholar
  13. 13.
    Sherry L, Ramage G, Kean R et al (2017) Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris. Emerg Infect Dis 23(2):328–331CrossRefGoogle Scholar
  14. 14.
    Fakhim H, Vaezi A, Dannaoui E et al (2018) Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in murine model. Mycoses 2018:1–6Google Scholar
  15. 15.
    Chatterjee S, Alampalli S, Nageshan RK et al (2015) Draft genome of commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genomics 16:686CrossRefGoogle Scholar
  16. 16.
    Sharma D, Kumar N, Pandey R et al (2016) Whole genome sequencing of emerging multidrug resistant Candida auris isolates in India demonstrates low genetic variation. New Microbes New Infect 13:77–82CrossRefGoogle Scholar
  17. 17.
    Munoz JF, Gade L, Chow NA, et al (2018) Genomic basis of multidrug resistance mating and virulence in Candida auris and related emerging species. bioRxiv 299917.
  18. 18.
    Sears D, Schwartz BS (2017) Candida auris: an emerging multidrug-resistant pathogen. Int J Infect Dis 63:95–98CrossRefGoogle Scholar
  19. 19.
    Coleman DA, Oh SH, Zhao X et al (2009) Monoclonal antibodies specific for Candida albicans ALS3 that immunolabel fungal cells in vitro and in vivo and block adhesion to host surfaces. J Microbiol Methods 78:71–78CrossRefGoogle Scholar
  20. 20.
    Mishra NN, Ali S, Shukla PK (2015) A monoclonal antibody against 47.2 kDa cell surface antigen prevents adherence and affects biofilm formation of Candida albicans. World J Microbiol Biotechnol 31:11–21CrossRefGoogle Scholar
  21. 21.
    Torosantucci A, Tumbarello M, Bromuro C et al (2017) Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients. Sci Rep 7:2722.
  22. 22.
    Gillum AM, Tsay EY, Kirsch DR (1984) Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 198:179–182CrossRefGoogle Scholar
  23. 23.
    Ramage G, Van de Walle K, Wickes BL, Lopez-Ribot JL (2001a) Standardized method for in vitro antifungal susceptibility testing of Candida albicans. Antimicrob Agents Chemother 45(9):2475–2479CrossRefGoogle Scholar
  24. 24.
    Bujdáková H, Lell C, Gruber A et al (1999) The influence of subinhibitory concentrations of conventional and experimental antifungal drugs on the expression of the iC3b binding protein in Candida albicans strains during filamentation. Pathog Dis 26(1):1–10Google Scholar
  25. 25.
    Lohse MB, Gulati M, Johnson AD, Nobile CJ (2018) Development and regulation of single and multi-species Candida albicans biofilms. Nat Rev Microbiol 16(1):19–31CrossRefGoogle Scholar
  26. 26.
    Ramage G, Vandewalle K, Wickes NL, López-Ribot JL (2001b) Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol 18:163–170Google Scholar
  27. 27.
    Ramage G, Rajendran R, Sherry L, Williams C (2012) Fungal biofilm resistance. Int J Microbiol 2012:528521CrossRefGoogle Scholar
  28. 28.
    Paulovičová E, Bujdáková H, Chupáčová J et al (2015) Humoral immune response to Candida albicans complement receptor 3-related protein in the atopic subjects with vulvovaginal candidiasis. Novel sensitive marker for Candida infection. FEMS Yeast Res 15.
  29. 29.
    Alaei S, Larcher C, Ebenbichler C et al (1993) Isolation and biochemical characterization of the iC3b receptor of Candida albicans. Infect Immun 61:1395–1399Google Scholar
  30. 30.
    De Bernardis F, Amacker M, Arancia S et al (2012) A virosomal vaccine against candida vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine 30(30):4490–4498CrossRefGoogle Scholar
  31. 31.
    Fujibayashi T, Nakamura M, Tominaga A et al (2009) Effects of IgY against Candida albicans and Candida spp. adherence and biofilm formation. Jpn J Infect Dis 62:337–342Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Jaroslava Dekkerová
    • 1
  • Jose L. Lopez-Ribot
    • 2
  • Helena Bujdáková
    • 1
    Email author
  1. 1.Department of Microbiology and Virology, Faculty of Natural SciencesComenius University in BratislavaBratislavaSlovakia
  2. 2.Department of Biology and South Texas Center for Emerging Infectious DiseasesThe University of Texas at San AntonioSan AntonioUSA

Personalised recommendations